Milne A C, Potter J, Avenell A
Health Services Research Unit (Foresterhill Lea), University of Aberdeen, Foresterhill, Aberdeen, Aberdeenshire, Scotland, UK, AB25 2ZD.
Cochrane Database Syst Rev. 2002(3):CD003288. doi: 10.1002/14651858.CD003288.
This review was carried out because evidence for the effectiveness of nutritional supplements containing protein and energy which are often prescribed for elderly people is limited. Furthermore malnutrition is more common in this age group and deterioration of nutritional status can occur during a stay in hospital. It is important to establish whether supplementing the diet with protein and energy is an effective way of improving outcomes for older people at risk from malnutrition.
This review examines the evidence from trials for improvement in nutritional status and clinical outcomes when extra protein and energy food were provided, usually in the form of commercial 'sip-feeds'.
We searched The Cochrane Library (issue 1, 2001), MEDLINE (1966 to February 2001), EMBASE (1980 to March 2001), Health star (1975 to March 2001), CINAHL (1982 to Jan 2001), BIOSIS (1985 to March 2001) and CAB abstracts (1973 to March 2001). We also hand searched nutrition journals and reference lists and contacted 'sip-feed' manufacturers. Date of most recent search: March 2001.
Randomised controlled trials and quasi-randomised controlled trials of oral protein and energy supplementation in older people with the exception of groups recovering from cancer treatment or in critical care.
Two reviewers independently assessed trials prior to inclusion and independently extracted data and assessed trial quality; any differences were resolved by reaching consensus. Authors of trials were contacted for further information as necessary.
Thirty-one trials with 2464 randomised participants have been included in the review. Most included trials had poor study quality. Mortality data were combined for meta-analysis from twenty-two trials (1755 participants). The Relative Risk (RR) indicated a lower mortality in the supplemented group compared with the control group (0.67; 95% confidence interval (CI) 0.52 to 0.87). The risk of complications (total complications if available, otherwise for example the number of infections by the end of follow-up) from nine trials (608 participants) showed no significant difference (RR 0.93, 95% CI 0.77 to 1.13). We were unable to combine trials for meta-analyses of functional outcome, for example grip strength, walking distance and Barthel Index, however there was little evidence of benefit to functional outcomes from individual studies. Data describing length of stay were available from seven trials (658 participants). There was some indication that mean length of stay was shorter for the supplemented groups (-3.4 days, 95% CI -6.12 to -0.69).
REVIEWER'S CONCLUSIONS: Supplementation appears to produce a small but consistent weight gain. There was a statistically significant beneficial effect on mortality and a shorter length of hospital stay. Additional data from large-scale multi-centre trials are still required to provide clear evidence of benefit from protein and energy supplements on mortality and length of hospital stay. Too few data were reported and the time scale of most studies was too short to have a realistic chance of detecting differences in morbidity, functional status and quality of life. Furthermore, most trials do not address the organisational and practical challenges faced by practitioners trying to meet the individual needs and preferences of those at risk from malnutrition.
进行这项综述是因为针对老年人经常开具的含蛋白质和能量的营养补充剂有效性的证据有限。此外,营养不良在该年龄组更为常见,且住院期间营养状况可能恶化。确定通过补充蛋白质和能量来改善有营养不良风险的老年人的预后是否是一种有效方法很重要。
本综述考察了提供额外蛋白质和能量食物(通常为商业“流食”形式)时,来自试验中关于营养状况改善和临床预后的证据。
我们检索了考克兰图书馆(2001年第1期)、医学索引数据库(1966年至2001年2月)、荷兰医学文摘数据库(1980年至公元2001年3月)、健康之星数据库(1975年至2001年3月)、护理学与健康领域数据库(1982年至2001年1月)、生物学文摘数据库(1985年至2001年3月)和国际农业与生物科学中心数据库(1973年至2001年3月)。我们还手工检索了营养学期刊和参考文献列表,并联系了“流食”制造商。最近一次检索日期:2001年3月。
除了从癌症治疗中恢复的人群或重症监护人群外,针对老年人口服补充蛋白质和能量的随机对照试验和半随机对照试验。
两名综述作者在纳入试验前独立评估试验,并独立提取数据和评估试验质量;如有任何差异,则通过达成共识来解决。必要时联系试验作者获取更多信息。
本综述纳入了31项试验,共2464名随机参与者。大多数纳入试验的研究质量较差。对来自22项试验(1755名参与者)的死亡率数据进行了合并以进行荟萃分析。相对风险(RR)表明,补充组的死亡率低于对照组(0.67;95%置信区间(CI)0.52至0.87)。来自9项试验(608名参与者)的并发症风险(如有总并发症数据则采用总并发症数据,否则例如采用随访结束时的感染次数)显示无显著差异(RR 0.93,95% CI 0.77至1.13)。我们无法对功能预后(例如握力、行走距离和巴氏指数)的试验进行合并荟萃分析,然而,个体研究几乎没有证据表明对功能预后有益。有7项试验(658名参与者)提供了关于住院时间的数据。有迹象表明补充组的平均住院时间较短(-3.4天,95% CI -6.12至-0.69)。
补充似乎能带来小幅度但持续的体重增加。对死亡率有统计学上的显著有益影响,且住院时间缩短。仍需要大规模多中心试验的更多数据,以提供关于蛋白质和能量补充剂对死亡率和住院时间有益的明确证据。报告的数据太少,且大多数研究的时间跨度太短,不太可能实际检测到发病率、功能状态和生活质量方面的差异。此外,大多数试验未解决从业者在试图满足有营养不良风险者的个体需求和偏好时所面临的组织和实际挑战。